AML 17: A Programme of Treatment Development in Younger Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome

Trial Profile

AML 17: A Programme of Treatment Development in Younger Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Arsenic trioxide (Primary) ; Clofarabine (Primary) ; Gemtuzumab ozogamicin (Primary) ; Laromustine (Primary) ; Cytarabine; Daunorubicin; Etoposide; Everolimus; Fludarabine; Idarubicin; Lestaurtinib; Temsirolimus; Tretinoin
  • Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Myelodysplastic syndromes
  • Focus Registrational; Therapeutic Use
  • Acronyms AML-17
  • Most Recent Events

    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2015 Primary endpoint (death rate) has not been met as results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2015 Primary endpoint (relapse rate) has been met as results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top